TNFRSF1B and cancer: The development of novel therapy based on selective inhibition of signaling via p75 could be an effective anti-angiogenic and pro-apoptotic mono-therapy, as well as a part of combination anti-cancer therapy that will help to sensitize tumor cells and tumor ECs to cytotoxic effects of conventional treatments such as chemotherapy [3] or radiation [12], thereby improving the outcome and decreasing toxicity and mortality.